Department of Physiology, Tulane Hypertension and Renal Center of Excellence, Tulane University School of Medicine, New Orleans, Louisiana.
Am J Med Sci. 2012 Oct;344(4):301-6. doi: 10.1097/MAJ.0b013e3182410d1e.
This study was performed to determine whether chronic direct renin inhibition can prevent the development of slowly progressive angiotensin (ANG) II-dependent hypertension and the associated derangements in renal function in Cyplal-Ren2 transgenic rats with inducible expression of the Ren2 gene.
Male Cyplal-Ren2 rats (n = 6) were fed a normal diet containing 0.15% indole-3-carbinol (I3C) for 16 days to induce slowly progressive ANG II-dependent hypertension. Conscious systolic blood pressure was measured daily using tail-cuff plethysmography. The rats were then anesthetized with pentobarbital sodium and surgically prepared for the measurement of mean arterial pressure (MAP) and renal hemodynamics and excretory function.
In rats induced with I3C, systolic blood pressure increased by day 3 (130 ± 7-160 ± 5 mm Hg, P < 0.01) and continued to increase to 191 ± 6 mm Hg (P < 0.001) by day 16. In a separate group of rats (n = 6), chronic administration of the direct renin inhibitor, aliskiren (30 mg/kg/d, sc), prevented the development of hypertension (113 ± 5 versus 114 ± 5 mm Hg, not significant). Rats treated with aliskiren exhibited significantly lower mean arterial pressure (138 ± 4 versus 201 ± 6 mm Hg, P < 0.001), renal vascular resistance (23 ± 4 versus 38 ± 3 mm Hg/mL/min · g, P < 0.01), urine flow (17.6 ± 1.4 versus 25.1 ± 2.9 μL/min, P < 0.05) and urinary sodium excretion (1.11 ± 0.32 versus 2.35 ± 0.28 μEq/min, P < 0.05) and higher renal plasma flow (4.22 ± 0.23 versus 2.56 ± 0.21 mL/min · g, P < 0.01) and glomerular filtration rate (1.19 ± 0.07 versus 0.78 ± 0.08 mL/min · g, P< 0.01), compared with induced rats not treated chronically with aliskiren.
The present findings demonstrate that chronic direct renin inhibition with aliskiren prevents the development of ANG II-dependent hypertension and the associated derangements in renal hemodynamics and excretory function in Cyplal-Ren2 transgenic rats.
本研究旨在探讨慢性直接肾素抑制是否能预防 Cyplal-Ren2 转基因大鼠中可诱导表达 Ren2 基因的缓慢进行性血管紧张素(ANG)II 依赖性高血压的发展,并预防相关的肾功能障碍。
雄性 Cyplal-Ren2 大鼠(n=6)在含有 0.15%吲哚-3-甲醇(I3C)的正常饮食中喂养 16 天,以诱导缓慢进行性 ANG II 依赖性高血压。使用尾套测压法每天测量清醒状态下的收缩压。然后,大鼠用戊巴比妥钠麻醉,并进行平均动脉压(MAP)和肾血流动力学及排泄功能的测量。
在接受 I3C 诱导的大鼠中,收缩压在第 3 天(130±7-160±5mmHg,P<0.01)升高,并持续升高至第 16 天的 191±6mmHg(P<0.001)。在另一组大鼠(n=6)中,慢性给予直接肾素抑制剂阿利克仑(30mg/kg/d,sc)可预防高血压的发生(113±5 与 114±5mmHg,无显著性差异)。用阿利克仑治疗的大鼠平均动脉压(138±4 与 201±6mmHg,P<0.001)、肾血管阻力(23±4 与 38±3mmHg/mL/min·g,P<0.01)、尿流量(17.6±1.4 与 25.1±2.9μL/min,P<0.05)和尿钠排泄量(1.11±0.32 与 2.35±0.28μEq/min,P<0.05)均较低,而肾血浆流量(4.22±0.23 与 2.56±0.21mL/min·g,P<0.01)和肾小球滤过率(1.19±0.07 与 0.78±0.08mL/min·g,P<0.01)较高,与未接受慢性阿利克仑治疗的诱导大鼠相比。
本研究结果表明,慢性给予阿利克仑抑制直接肾素可预防 Cyplal-Ren2 转基因大鼠中 ANG II 依赖性高血压的发生,并预防相关的肾血流动力学和排泄功能障碍。